OPKO Health, Inc. $OPK Shares Sold by Deutsche Bank AG

Deutsche Bank AG cut its holdings in OPKO Health, Inc. (NASDAQ:OPK) by 9.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 281,647 shares of the biotechnology company’s stock after selling 28,220 shares during the quarter. Deutsche Bank AG’s holdings in OPKO Health were worth $468,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in OPK. Wells Fargo & Company MN boosted its position in shares of OPKO Health by 14.9% during the 4th quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company’s stock valued at $337,000 after purchasing an additional 29,738 shares in the last quarter. Raymond James Financial Inc. purchased a new position in OPKO Health in the 4th quarter worth about $221,000. Barclays PLC increased its stake in OPKO Health by 68.7% in the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company’s stock worth $1,347,000 after purchasing an additional 373,032 shares in the last quarter. MetLife Investment Management LLC increased its stake in OPKO Health by 40.8% in the 4th quarter. MetLife Investment Management LLC now owns 202,165 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 58,589 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in OPKO Health by 4.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 18,571 shares in the last quarter. Institutional investors own 64.63% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $1.32 per share, with a total value of $891,000.00. Following the acquisition, the chief executive officer directly owned 214,676,448 shares in the company, valued at $283,372,911.36. The trade was a 0.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 49.69% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on OPK. LADENBURG THALM/SH SH raised OPKO Health to a “strong-buy” rating in a research note on Tuesday, July 8th. Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Thursday, May 1st. Zacks Research raised OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Finally, Wall Street Zen downgraded OPKO Health from a “hold” rating to a “sell” rating in a report on Monday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $2.75.

OPKO Health Trading Up 2.2%

Shares of NASDAQ:OPK opened at $1.42 on Thursday. OPKO Health, Inc. has a 52-week low of $1.11 and a 52-week high of $2.04. The company has a market capitalization of $1.13 billion, a P/E ratio of -5.68 and a beta of 1.19. The company has a 50-day simple moving average of $1.34 and a 200 day simple moving average of $1.46. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The firm had revenue of $156.80 million during the quarter, compared to analyst estimates of $165.74 million. During the same quarter last year, the business posted ($0.01) earnings per share. The company’s revenue for the quarter was down 13.9% on a year-over-year basis. Sell-side analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.